Filing Details

Accession Number:
0001209191-20-052246
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-09-28 17:55:21
Reporting Period:
2020-09-25
Accepted Time:
2020-09-28 17:55:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1382101 Sutro Biopharma Inc. STRO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1326592 Trevor Hallam C/O Sutro Biopharma, Inc.
310 Utah Avenue, Suite 150
South San Francisco CA 94080
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-09-25 11,019 $0.00 27,809 No 4 M Direct
Common Stock Disposition 2020-09-25 3,810 $10.30 23,999 No 4 F Direct
Common Stock Acquisiton 2020-09-25 6,887 $0.00 30,886 No 4 M Direct
Common Stock Disposition 2020-09-25 2,381 $10.30 28,505 No 4 F Direct
Common Stock Disposition 2020-09-28 975 $10.26 27,530 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 F Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit (RSU) Disposition 2020-09-25 11,019 $0.00 11,019 $0.00
Common Stock Restricted Stock Unit (RSU) Disposition 2020-09-25 6,887 $0.00 6,887 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,019 2021-09-26 No 4 M Direct
0 2020-09-26 No 4 M Direct
Footnotes
  1. Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
  2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the holder.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.41 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
  5. The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.
  6. The RSUs vest as to 1/2 of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.